Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes

Diabetes and Metabolism

Volumn 39, Issue 1, 2013, Pages 6-15

  Vora, J ^a   Bain, S C ^b   Damci, T ^c   Dzida, G ^d   Hollander, P ^e   Meneghini, L F ^f   Ross, S A ^g  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c ISTANBUL UNIVERSITY   (Turkey)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

DPP IV inhibitors; GLP 1 analogue; HbA1c; Insulin; Review; Type 2 diabetes mellitus; Weight

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

DECREASED APPETITE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG TOLERABILITY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN TREATMENT; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; REVIEW; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; METFORMIN; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84874288415     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.08.002     Document Type: Review

References (73)

1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
2. Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. J Annu Diabetol Hotel Dieu 2007, 13-20.
3. Ban K., Hui S., Drucker D.J., Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009, 3:245-259.
4. Hermansen K., Mortensen L.S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30:1127-1142.
5. Choy C.K., Rodgers J.E., Nappi J.M., Haines S.T. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008, 28:170-192.
6. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
7. Nauck M.A., Heimesaat M.M., Behle K., Holst J.J., Nauck M.S., Ritzel R., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
8. Barber T.M., Begbie H., Levy J. The incretin pathway as a new therapeutic target for obesity. Maturitas 2010, 67:197-202.
9. Chaudhri O., Small C., Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006, 361:1187-1209.
10. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
11. Bosi E. Time for testing incretin therapies in early type 1 diabetes. J Clin Endocrinol Metab 2010, 95:2607-2609.
12. Tews D., Werner U., Eckel J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008, 40:172-180.
13. Treiman M., Elvekjaer M., Engstrom T., Jensen J.S. Glucagon-like peptide 1--a cardiologic dimension. Trends Cardiovasc Med 2010, 20:8-12.
14. Meier J.J., Nauck M.A. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function. Diabetes 2010, 59:1117-1125.
15. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91(1):301-307.
16. Bell T.J., Wright E.E. Can therapies that target the incretin system improve our ability to treat type 2 diabetes. J Natl Med Assoc 2010, 102:511-523.
17. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, 2:CD006739.
18. Scheen A.J., Radermecker R.P. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010, 375:1410-1412.
19. Schernthaner G., Barnett A.H., Betteridge D.J., Carmena R., Ceriello A., Charbonnel B., et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion. A critical analysis. Diabetologia 2010, 53:1258-1269.
20. Vilsboll T., Rosenstock J., Yki-Jarvinen H., Cefalu W.T., Chen Y., Luo E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:167-177.
21. Buse J.B., Bergenstal R.M., Glass L.C., Heilmann C.R., Lewis M.S., Kwan A.Y., et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
22. 1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009, 11:1145-1152.
23. Yoon N.M., Cavaghan M.K., Brunelle R.L., Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009, 31:1511-1523.
24. DeFronzo R.A. Banting lecture from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
25. Owens D.R., Luzio S.D., Coates P.A. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabet Med 1996, 13(9 Suppl. 6):S19-S24.
26. Coates P.A., Ollerton R.L., Luzio S.D., Ismail I., Owens D.R. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994, 26:177-187.
27. Ahren B. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 2009, 58:726-731.
28. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011, 13(Suppl. 1):126-132.
29. Dunning B.E., Foley J.E., Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005, 48:1700-1713.
30. Peter R., Okoseime O.E., Rees A., Owens D.R. Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009, 7:68-74.
31. Ahren B., Foley J.E., Ferrannini E., Matthews D.R., Zinman B., Dejager S., et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010, 33:730-732.
32. Holst J.J., Christensen M., Lund A., de H.J., Svendsen B., Kielgast U., et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011, 13(Suppl. 1):89-94.
33. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
34. Holman R.R., Farmer A.J., Davies M.J., Levy J.C., Darbyshire J.L., Keenan J.F., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736-1747.
35. Meneghini L., Liebl A., Abrahamson M.J. Insulin detemir: a historical perspective on a modern basal insulin analogue. Prim Care Diabetes 2010, 4(Suppl. 1):S31-S42.
36. Garvey W.T., Olefsky J.M., Griffin J., Hamman R.F., Kolterman O.G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985, 34:222-234.
37. Li Y., Xu W., Liao Z., Yao B., Chen X., Huang Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27:2597-2602.
38. Degn K.B., Brock B., Juhl C.B., Djurhuus C.B., Grubert J., Kim D., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
39. Ahren B., Schweizer A., Dejager S., Dunning B.E., Nilsson P.M., Persson M., et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1236-1243.
40. Russell-Jones D., Khan R. Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab 2007, 9:799-812.
41. Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition+metformin. Vasc Health Risk Manag 2008, 4:383-394.
42. Mannucci E., Tesi F., Bardini G., Ognibene A., Petracca M.G., Ciani S., et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004, 17:336-342.
43. Migoya E.M., Bergeron R., Miller J.L., Snyder R.N., Tanen M., Hilliard D., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88:801-808.
44. Cuthbertson J., Patterson S., O'Harte F.P., Bell P.M. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 2011, 60:52-56.
45. Green B.D., Irwin N., Duffy N.A., Gault V.A., O'Harte F.P., Flatt P.R. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006, 547:192-199.
46. Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., Williams-Herman D.E. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
47. Jadzinsky M., Pfutzner A., Paz-Pacheco E., Xu Z., Allen E., Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622.
48. Bunck M.C., Corner A., Eliasson B., Heine R.J., Shaginian R.M., Taskinen M.R., et al. Effects of exenatide on measures of beta-cell function after 3years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011, 34:2041-2047.
49. Thong K.Y., Jose B., Blann A.D., Cull M.L., Mills A.P., Sathyapalan T., et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract 2011, 93:e87-e91.
50. Thong K.Y., Jose B., Sukumar N., Cull M.L., Mills A.P., Sathyapalan T., et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011, 13:703-710.
51. Nayak U.A., Govindan J., Baskar V., Kalupahana D., Singh B.M. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010, 103:687-694.
52. 1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012, 6(1):41-46.
53. Lane W., Weinrib S., Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011, 13:592-595.
54. Kielgast U., Krarup T., Holst J.J., Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 34:1463-1468.
55. Rother K.I., Spain L.M., Wesley R.A., Digon B.J., Baron A., Chen K., et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009, 32:2251-2257.
56. Varanasi A., Bellini N., Rawal D., Vora M., Makdissi A., Dhindsa S., et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011, 165:77-84.
57. Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
58. Fonseca V., Baron M., Shao Q., Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008, 40:427-430.
59. Bloomgarden Z.T., Dodis R., Viscoli C.M., Holmboe E.S., Inzucchi S.E. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006, 29:2137-2139.
60. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010, 27:309-317.
61. Sherifali D., Nerenberg K., Pullenayegum E., Cheng J.E., Gerstein H.C. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010, 33:1859-1864.
62. Arnolds S., Dellweg S., Clair J., Dain M.P., Nauck M.A., Rave K., et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010, 33:1509-1515.
63. deVries J.H., Bain S.C., Rodbard H.W., Seufert J., D'Alessio D., Thomsen A.B., et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012, 35(7):1446-1454.
64. Hollander P., Raslova K., Skjoth T.V., Rastam J., Liutkus J.F. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 2011, 13:268-275.
65. Pratley R.E., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
66. Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
67. Malm-Erjefalt M., Bjornsdottir I., Vanggaard J., Helleberg H., Larsen U., Oosterhuis B., et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010, 38:1944-1953.
68. Foley J.E., Ligueros-Saylan M., He Y.L., Holst J.J., Deacon C.F., Dunning B.E., et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 2008, 40:727-730.
69. Kielgast U., Holst J.J., Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009, 5:266-275.
70. Drucker D.J., Sherman S.I., Bergenstal R.M., Buse J.B. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab 2011, 96:2027-2031.
71. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993, 38:665-673.
72. Mudaliar S., Henry R.R. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010, 123(3 Suppl.):S19-S27.
73. Sonne D.P., Engstrom T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249.